Navigation Links
KV Pharmaceutical Company Reduces Workforce
Date:2/9/2009

Layoffs result from recent challenges, effort to reduce costs

ST. LOUIS, Feb. 9 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb) announced today it is in the process of reducing its workforce by approximately 700 jobs. The action is part of an overall cost-cutting program as the company works toward resuming full operation. The company has encountered a number of substantial challenges over the past months, including a voluntary suspension of product manufacturing and shipment, as well as voluntary recalls of its products.

"KV Pharmaceutical plans to emerge from these challenges on a solid foundation of a smaller, more focused organization and the return to providing excellent products to our customers," said David Van Vliet, interim President and CEO. "The need to reduce our employee base is regrettable and one of the most difficult parts of our program to resume manufacturing and shipping product."

The KV workforce reduction includes a combination of terminations and layoffs. The company expects to recall some employees when production and shipment of approved products resume.

To resume product shipments as quickly as possible, the company is currently working with Lachman Consulting, a third-party consulting group, to enhance KV's current Good Manufacturing Practice (cGMP) processes and quality systems. KV continues to work in full cooperation with the U.S. Food and Drug Administration (FDA).

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology distinguished products through ETHEX Corporation, a subsidiary that competes with branded products, and Ther-Rx Corporation, the company's b
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Amy Norton HealthDay Reporter , ... part in clinical trials of new heart disease treatments are ... new study confirms. Experts said the findings, which appear ... Association , aren,t surprising -- but they are troubling. ... more select patient population that is not fully representative of ...
(Date:8/27/2014)... from our parents shapes many aspects of our lives. ... epigenome that is set during development, but can be ... by those of our parents and grandparents. , The ... supporting proteins that determine whether genes are expressed or ... our own health, but also that it may be ...
(Date:8/27/2014)... spending for commercially insured individuals is due primarily to ... use, according to a new study led by researchers ... Practice, published in the August issue of the ... increasing concern that consolidation in the health care marketplace ... ultimately, consumers," said Carrie Colla, PhD, assistant professor at ...
(Date:8/27/2014)... 27, 2014 CarePoint Health is ... Hoboken Pediatrics has joined our network, CarePoint Health ... Dr. Piotr Oko, Dr. Yanina Meshko and Dr. ... skilled and experienced physicians comprise CarePoint Health Medical ... practices in Hudson County, representing a wide range ...
(Date:8/27/2014)... Scientists at The Scripps Research Institute (TSRI) have ... can be associated with alcohol dependence. , This ... type 1 (Nf1), which TSRI scientists found is linked ... Nf1 regulates gamma-aminobutyric acid (GABA), a neurotransmitter that lowers ... novel and seminal study provides insights into the cellular ...
Breaking Medicine News(10 mins):Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 2Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 3Health News:Scientists map the 'editing marks' on fly, worm, human genomes 2Health News:Scientists map the 'editing marks' on fly, worm, human genomes 3Health News:Scientists map the 'editing marks' on fly, worm, human genomes 4Health News:Tracking spending among the commercially insured 2Health News:Hoboken Pediatrics Joins CarePoint Health Medical Group 2Health News:Hoboken Pediatrics Joins CarePoint Health Medical Group 3Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2
... could deter more than 100,000 Californians from enrolling in ... today by the California Pan-Ethnic Health Network, the UCLA ... Center for Labor Research and Education. ... that estimates the likely enrollment in health care reform ...
... , WEDNESDAY, Feb. 29 (HealthDay News) -- Federal ... helped provide guidance on whether it,s safe or effective for ... The Institute of Medicine (IOM) report noted, however, ... drugs in newborns or the long-term effects of drugs on ...
... people with diabetes could be adapted into a home DNA ... and bacteria in human body fluids, in food and in ... report on this adaptation of the ubiquitous personal glucose monitor, ... journal Analytical Chemistry . Yi Lu and Yu ...
... (FDA) announced it is revising safety information on the labels ... class of drugs that work in the liver to prevent ... at lowering the LDL (bad) cholesterol, but also have modest ... cholesterol. High cholesterol is a risk factor for ...
... HealthDay Reporter , TUESDAY, Feb. 28 (HealthDay News) ... emergency room with fevers are making the right decision, ... not be generalized, and therefore not approached, as a ... Dr. Yvette van Ierland, from the department of pediatrics ...
... , TUESDAY, Feb. 28 (HealthDay News) -- Taking the ... fetus and lead to poorer motor control in infants, a ... their substance-abuse history before and during pregnancy. The women were ... Infancy Study, which looks at recreational drug use among pregnant ...
Cached Medicine News:Health News:Study: Over 100,000 Californians likely to miss out on health care due to language barriers 2Health News:Efforts to Improve Research on Kids' Drugs Paying Off: Report 2Health News:American Heart Association comment: FDA announces safety changes on labeling for some statins 2Health News:Parents Often Right to Bring Kids With Fever to the ER: Study 2Health News:Parents Often Right to Bring Kids With Fever to the ER: Study 3Health News:Ecstasy Use During Pregnancy May Harm Fetus: Study 2
(Date:8/27/2014)... REDWOOD CITY, Calif. , Aug. 27, 2014 ... in emergency response system design, blended emergency medical ... for CPR/AED (automated external defibrillator) training from the ... and the Army Reserve 81 st ... Homeland Security and Investigations contract includes nationwide CPR/AED/First ...
(Date:8/27/2014)... WARSAW, Ind. , Aug. 27, 2014  Zimmer ... in musculoskeletal care, announced that it will be participating ... the Grand Hyatt in New York, New ... David Dvorak , President and CEO of Zimmer, will ... Binder , President and CEO of Biomet, will join ...
(Date:8/27/2014)... Aug. 27, 2014 Asterias Biotherapeutics Inc. (OTCBB: ... Drug Administration (FDA) to initiate a Phase 1/2a clinical ... cervical spinal cord injury.  The approved trial follows the ... the product, and is designed to assess safety and ... complete cervical spinal cord injuries, the first targeted indication ...
Breaking Medicine Technology:Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 2Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5
... 3, 2007 - Insmed Inc.,(Nasdaq:INSM) today announced positive ... company's drug, IPLEX(TM), in,patients with myotonic muscular dystrophy ... conducted at,the University of Rochester School of Medicine ... doses of IPLEX up to 1,mg/kg/day in six ...
... Ferret Study to be Part of Data Package ... 2007 /PRNewswire-FirstCall/ -- Novavax,Inc. said today that it ... challenge to ferrets inoculated with its pandemic,influenza vaccine, ... on,schedule later this year. , In the study, ...
Cached Medicine Technology:Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 2Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 3Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 4Novavax Reports Positive Pre-Clinical Study Results from Live Virus,Challenge to Pandemic Flu Vaccine 2Novavax Reports Positive Pre-Clinical Study Results from Live Virus,Challenge to Pandemic Flu Vaccine 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: